SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:9935919c-6fe1-4748-8fc2-a81b0b406b6b"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:9935919c-6fe1-4748-8fc2-a81b0b406b6b" > EGLN2 DNA methylati...

EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC

Zhang, Ruyang (författare)
Nanjing Medical University,Harvard University
Lai, Linjing (författare)
Nanjing Medical University
He, Jieyu (författare)
Nanjing Medical University
visa fler...
Chen, Chao (författare)
Nanjing Medical University
You, Dongfang (författare)
Nanjing Medical University
Duan, Weiwei (författare)
Nanjing Medical University
Dong, Xuesi (författare)
Nanjing Medical University,Southeast University
Zhu, Ying (författare)
Nanjing Medical University
Lin, Lijuan (författare)
Nanjing Medical University
Shen, Sipeng (författare)
Nanjing Medical University,Harvard University
Guo, Yichen (författare)
Harvard University
Su, Li (författare)
Nanjing Medical University,Harvard University
Shafer, Andrea (författare)
Massachusetts General Hospital,Harvard University
Moran, Sebastian (författare)
Catalan Institution for Research and Advanced Studies,Bellvitge Biomedical Research Institute,University of Barcelona
Fleischer, Thomas (författare)
Oslo university hospital
Bjaanæs, Maria Moksnes (författare)
Oslo university hospital
Karlsson, Anna (författare)
Lund University,Lunds universitet,Forskningsgrupp Lungcancer,Forskargrupper vid Lunds universitet,Research Group Lung Cancer,Lund University Research Groups
Planck, Maria (författare)
Lund University,Lunds universitet,Forskningsgrupp Lungcancer,Forskargrupper vid Lunds universitet,Research Group Lung Cancer,Lund University Research Groups
Staaf, Johan (författare)
Lund University,Lunds universitet,Forskningsgrupp Lungcancer,Forskargrupper vid Lunds universitet,Research Group Lung Cancer,Lund University Research Groups
Helland, Åslaug (författare)
Oslo university hospital,University of Oslo
Esteller, Manel (författare)
Catalan Institution for Research and Advanced Studies,Bellvitge Biomedical Research Institute,University of Barcelona
Wei, Yongyue (författare)
Harvard University,Nanjing Medical University
Chen, Feng (författare)
Nanjing Medical University
Christiani, David C. (författare)
Massachusetts General Hospital,Nanjing Medical University,Harvard University
visa färre...
 (creator_code:org_t)
2019-01-31
2019
Engelska.
Ingår i: Epigenetics. - : Informa UK Limited. - 1559-2294 .- 1559-2308. ; 14:2, s. 118-129
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Hypoxia occurs frequently in human cancers and promotes stabilization and activation of hypoxia inducible factor (HIF). HIF-1α is specific for the hypoxia response, and its degradation mediated by three enzymes EGLN1, EGLN2 and EGLN3. Although EGLNs expression has been found to be related to prognosis of many cancers, few studies examined DNA methylation in EGLNs and its relationship to prognosis of early-stage non-small cell lung cancer (NSCLC). We analyzed EGLNs DNA methylation data from tumor tissue samples of 1,230 early-stage NSCLC patients, as well as gene expression data from The Cancer Genome Atlas. The sliding windows sequential forward feature selection method and weighted random forest were used to screen out the candidate CpG probes in lung adenocarcinomas (LUAD) and lung squamous cell carcinomas patients, respectively, in both discovery and validation phases. Then Cox regression was performed to evaluate the association between DNA methylation and overall survival. Among the 34 CpG probes in EGLNs, DNA methylation at cg25923056EGLN2 was identified to be significantly associated with LUAD survival (HR = 1.02, 95% CI: 1.01–1.03, P = 9.90 × 10–5), and correlated with EGLN2 expression (r =–0.36, P = 1.52 × 10–11). Meanwhile, EGLN2 expression was negatively correlated with HIF1A expression in tumor tissues (r =–0.30, P = 4.78 × 10–8) and significantly (P = 0.037) interacted with HIF1A expression on overall survival. Therefore, DNA methylation of EGLN2- HIF1A is a potential marker for LUAD prognosis and these genes are potential treatment targets for further development of HIF-1α inhibitors in lung cancer therapy.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Medicinsk genetik (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Medical Genetics (hsv//eng)

Nyckelord

DNA methylation
EGLN2
HIF1A
lung cancer
prognosis

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy